外科理论与实践

外科理论与实践 >

2024 , Vol. 29 >Issue 01: 1 - 4

DOI: https://doi.org/10.16139/j.1007-9610.2024.01.01

专家论坛

可切除胰腺癌新辅助治疗的研究及指南解读，肯定还是否定?

  • 张太平 ,
  • 翁桂湖 ,
  • 刘悦泽
展开
  • 中国医学科学院北京协和医学院北京协和医院基本外科，北京 100730
张太平，E-mail: tpingzhang@yahoo.com

收稿日期: 2023-11-30

  网络出版日期: 2024-05-14

基金资助

国家自然科学基金(81972258);国家自然科学基金(82272917);国家重点研发计划(2018YFE0118600)

收起

Research and guidelines interpretation of neoadjuvant therapy for resectable pancreatic cancer, promising or limited?

  • ZHANG Taiping ,
  • WENG Guihu ,
  • LIU Yueze
Expand
  • Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences，Beijing 100730, China

Received date: 2023-11-30

  Online published: 2024-05-14

Fold

摘要

作为一种系统性疾病，胰腺癌恶性程度高，复发转移率高，诊治与管理尤为困难。近年来随着新辅助治疗理念的不断推广，胰腺癌的治疗愈发强调在全流程、多方位管理中制定综合性、个性化治疗方案。然而，目前针对新辅助治疗在可切除胰腺癌中的应用尚存诸多争议。本文拟结合国、内外指南及最新研究进展，针对可切除胰腺癌病人实施新辅助治疗中的热点话题及相关争议进行探讨，以期推动新辅助治疗在可切除胰腺癌中的规范化应用。

关键词： 可切除胰腺癌; 新辅助治疗; 进展与争议; 规范化治疗

本文引用格式

张太平 , 翁桂湖 , 刘悦泽 . 可切除胰腺癌新辅助治疗的研究及指南解读，肯定还是否定?[J]. 外科理论与实践, 2024 , 29(01) : 1 -4 . DOI: 10.16139/j.1007-9610.2024.01.01

Abstract

As a systemic disease, pancreatic cancer is highly malignant and has a high rate of recurrence and metastasis, which makes it particularly difficult in diagnosis, treatment and management. In recent years, with the concept of neoadjuvant therapy deeply rooted in the hearts of the people, the treatment of pancreatic cancer has increasingly emphasized the development of comprehensive and individualized treatment schemes in the whole process and multi-dimensional management of pancreatic cancer patients. However, there still remain many controversies about the application of neoadjuvant therapy for resectable pancreatic cancer. This review intended to discuss the hot topics and related controversies in the implementation of neoadjuvant therapy for patients with resectable pancreatic cancer based on domestic and foreign guidelines and the latest research progress, which may vastly promote the standardized application of neoadjuvant therapy for resectable pancreatic cancer.

Key words： Resectable pancreatic cancer; Neoadjuvant therapy; Progress and controversies; Standardized treatment

参考文献

[1] SPRINGFELD C, FERRONE C R, KATZ M H G, et al. Neoadjuvant therapy for pancreatic cancer[J]. Nat Rev Clin Oncol, 2023, 20(5):318-337.
[2] 孟令威, 吴仲, 彭兵. 胰腺癌新辅助化疗后的微创治疗[J]. 中国普外基础与临床杂志, 2023, 30(9):1025-1029.
  MENG L W, WU Z, PENG B. Minimally invasive treatment of pancreatic cancer after neoadjuvant chemotherapy[J]. Chin J Bases Clin Gen Surg, 2023, 30(9):1025-1029
[3] VERSTEIJNE E, VAN DAM J L, SUKER M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the dutch randomized PREOPANC trial[J]. J Clin Oncol, 2022, 40(11):1220-1230.
[4] SEUFFERLEIN T, UHL W, KORNMANN M, et al. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX) — a randomized phase Ⅱ trial of the AIO pancreatic cancer group[J]. Ann Oncol, 2023, 34(1):91-100.
[5] SOHAL D P S, DUONG M, AHMAD S A, et al. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial[J]. JAMA Oncol, 2021, 7(3):421-427.
[6] USON JUNIOR P L S, DIAS E SILVA D, DE CASTRO N M, et al. Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials[J]. ESMO Open, 2023, 8(1):100771.
[7] 杨尹默, 田孝东. 中国胰腺癌诊治指南(2021)[J]. 中国实用外科杂志, 2021, 41(7):725-738.
  YANG Y M, TIAN X D. Chinese guidelines for diagnosis and treatment of pancreatic cancer(2021)[J]. Chin J Pract Surg, 2021, 41(7):725-738.
[8] TEMPERO M A, MALAFA M P, AL-HAWARY M, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(4):439-457.
[9] WU V S, ELSHAMI M, STITZEL H J, et al. Why the treatment sequence matters: interplay between chemotherapy cycles received, cumulative dose intensity, and survival in resected early-stage pancreas cancer[J]. Ann Surg, 2023, 278(4):e677-e684.
[10] ZOU Y, GAO S, YU X, et al. Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage Ⅰ-Ⅲ pancreatic ductal adenocarcinoma: a retrospective cohort study[J]. Int J Surg, 2023, 109(6):1573-1583.
[11] STRICKLER J H, SATAKE H, GEORGE T J, et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer[J]. N Engl J Med, 2023, 388(1):33-43.
[12] BEKAII-SAAB T S, YAEGER R, SPIRA A I, et al. Adagrasib in advanced solid tumors harboring a KRASG12C mutation[J]. J Clin Oncol, 2023, 41(25):4097-4106.
[13] KING D, KAMRAN U, DOSANJH A, et al. Rate of pancreatic cancer following a negative endoscopic ultrasound and associated factors[J]. Endoscopy, 2022, 54(11):1053-1061.
[14] SAGAMI R, NAKAHODO J, MINAMI R, et al. True diagnostic ability of EUS-guided fine-needle aspiration/biopsy sampling for small pancreatic lesions ≤10 mm and salvage diagnosis by pancreatic juice cytology: a multicenter study[J]. Gastrointest Endosc, 2024, 99(1):73-80.
[15] VAN EIJCK C W F, MUSTAFA D A M, VADGAMA D, et al. Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with resected pancreatic cancer[J]. Gut, 2024, 73(2):311-324.
[16] NAKAJIMA K, INO Y, NAITO C, et al. Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5[J]. Br J Cancer, 2022, 126(4):628-639.
[17] BYRNE K T, BETTS C B, Mick R, et al. Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer[J]. Clin Cancer Res, 2021, 27(16):4574-4586.
[18] REDEGALLI M, GRASSINI G, MAGLIACANE G, et al. Routine molecular profiling in both resectable and unresectable pancreatic adenocarcinoma: relevance of cytologic samples[J]. Clin Gastroenterol Hepatol, 2023, 21(11):2825-2833.
[19] ECKER B L, TAO A J, JANSSEN Q P, et al. Genomic biomarkers associated with response to induction chemotherapy in patients with localized pancreatic ductal adenocarcinoma[J]. Clin Cancer Res, 2023, 29(7):1368-1374.
[20] ZHOU X, AN J, KURILOV R, et al. Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC[J]. Nat Cancer, 2023, 4(9):1362-1381.
Options
文章导航

/

〈 〉